INTRODUCTION
Hypoglycemia is common in neonates admitted to intensive care, and very preterm infants are also at risk of hyperglycemia, both of which have been associated with adverse neurodevelopment. Continuous glucose monitoring (CGM) has shown that abnormal glucose concentrations frequently go undetected in neonates, even with regular intermittent blood glucose testing. CGM has the potential to improve the detection and management of neonatal hypoglycemia and hyperglycemia, and may reduce the need for frequent blood sampling. However, CGM devices have not been approved for use in neonates, and there is as yet no evidence of clinical benefit from randomized trials. This review discusses the potential benefits and uses of CGM in neonates along with its limitations.
CONTINUOUS GLUCOSE MONITORING TECHNOLOGY FOR NEONATES
Although there are no CGM devices specifically designed or approved for use in neonates, as the size of these devices has decreased, it has become feasible to use CGM in even very preterm infants. Current CGM devices measure interstitial glucose concentration using a fine amperometric glucose oxidase needle sensor that is inserted into the subcutaneous tissue [1] . The sensor is powered by a recording or transmitting unit on the skin surface, which receives current from the electrode approximately every 10 s, and averages and processes this signal to give an output every 5 min. Blood glucose concentration is estimated from this signal using proprietary algorithms based on regular calibration to blood glucose measurements (minimum 12 hourly) [ ] reported that detachment of sensors was a problem in some very preterm infants, and that CGM had to be discontinued in two infants due to multiple detachments.
A significant limitation of current technology is that glucose concentrations are only provided in the range of 40 mg/dl (2.2 mmol/l) to 400 mg/dl (22 mmol/l), thus limiting assessment of neonatal hypoglycemia. However, for retrospective analysis, this can be overcome by point-to-point recalibration of the raw signal, which also improves the accuracy of CGM in the lower glucose range [9] . Another limitation is that sensors require a 'wetting' phase, which is typically around 2 h, but the time required for stabilization of the signal output has not been specifically studied in neonates. Both Harris et al. [10] and Beardsall et al. [8] found highest mean absolute error on day 1 after insertion, which may in part reflect increased error during the wetting phase.
POTENTIAL BENEFITS AND USES OF NEONATAL CONTINUOUS GLUCOSE MONITORING
CGM has several potential benefits in care of neonates at risk of dysglycemia. First, it may allow for decreased frequency of blood sampling and hence the number of heel pricks performed. For example, in a randomized trial of very low birth weight infants in the first 3 days after birth, Uettwiller et al. [5 && ] compared realtime CGM to intermittent capillary glucose testing with retrospective CGM (N ¼ 48). In the intermittent group, capillary blood glucose concentrations were measured 4 hourly, whereas in the CGM group, capillary glucose was measured only when CGM reported glucose concentrations below 60 mg/dl (3.3 mmol/l). The use of real-time CGM resulted in a 25% reduction in the number of capillary blood tests (P < 0.001), even though the number of hypoglycemic episodes, defined as consecutive CGM values less than 50 mg/dl (2.8 mmol/l), was similar in both groups. In infants born very preterm, neonatal pain-related stress has been associated with frontal and parietal cortical thinning at school age, independent of other neonatal risk factors [11] . Therefore, use of CGM to reduce the frequency of heel pricks in neonates may have beneficial effects on later development, but this requires confirmation in randomized trials.
Second, CGM may reduce exposure to hypoglycemia or hyperglycemia, due to either earlier detection or improved treatment of episodes. Studies in both preterm and at-risk term newborns have shown that episodes of hypoglycemia are common during neonatal transition, but many are not detected by intermittent blood glucose screening. For example, in the CHYLD study, a large prospective cohort (N ¼ 614) of term and late preterm infants born at risk of hypoglycemia, 25% of infants with hypoglycemia had low interstitial glucose concentrations [<47 mg/dl (<2.6 mmol/l)] for more than 5 h, despite regular blood testing and treatment by protocol. Further, nearly a quarter of infants with normal intermittent blood glucose testing had episodes of low glucose concentrations (>10 min) detected only by CGM [ CGM has shown that episodes of hyperglycemia are also common in preterm infants. For example, using masked CGM Beardsall et al. [13] identified hyperglycemia, defined as an interstitial glucose concentration more than 144 mg/dl (>8 mmol/l), for more than 10% of time (approximately 15 h) in the first week, in almost half of very low birth weight infants (N ¼ 188) and moderate-to-severe hyperglycemia [>180 mg/dl (>10 mmol/l)] in onethird. Galderisi et al. [7 && ] also found that mild hyperglycemia, defined as an interstitial glucose concentration more than 144-180 mg/dl (>8-10 mmol/l), occurred for more than 20 h in 25% of very preterm or very low birth weight infants (N ¼ 25) in the first week, although severe hyperglycemia [>180 mg/dl (>10 mmol/l)] was uncommon.
Two trials have evaluated whether using realtime CGM to guide clinical care in the first week after birth improves glucose stability in very preterm or very low birth weight infants. Uettwiller et al. [5 && ] found that using CGM to guide the need for blood glucose measurements not only reduced the frequency of blood tests but also reduced the median duration of hypoglycemic episodes by 51 min (P < 0.05). This was attributed primarily to earlier detection of episodes by CGM than by regular intermittent capillary blood glucose testing. Galderisi et al. [7 && ] compared use of a computer-adjusted glucose infusion rate based on either CGM alarm and trend data or intermittent capillary blood glucose concentrations (8 hourly) and found that neonates in the CGM group spent more time in the target glucose range of 72-144 mg/dl (4.0-8.0 mmol/l) (median percentage of time 84 vs. 68%, P < 0.001). This was due to less time in both the hypoglycemic and hyperglycemic range. Both trials were limited by use of glucometers rather than more accurate measurement methods for CGM calibration and intermittent glucose monitoring.
Although these trials suggest that CGM may be useful in improving glucose stability in preterm infants during the early neonatal period, it is not yet known if the use of CGM improves short-term or long-term clinical outcomes. In both trials, the CGM groups received more carbohydrate, possibly indicating higher fluid intake, which has been associated with increased risk of bronchopulmonary dysplasia [14] . CGM was also associated with increased use of intravenous dextrose boluses, which is concerning as higher glucose concentrations after neonatal hypoglycaemia may increase the risk of neurosensory impairment [12 & ]. Nevertheless, in the CHYLD study, infants with undetected and thus untreated hypoglycemic episodes (by CGM only) had poorer executive function at 4.5 years of age, suggesting that improved detection of episodes may potentially improve neurodevelopmental outcomes [15 & ]. This may be even more important for infants with additional neurological insults, such as hypoxic ischemic encephalopathy, although the accuracy of CGM in infants with severe illness, including those undergoing therapeutic hypothermia, is not known.
CGM may have a role in detecting late onset neonatal metabolic instability. CGM studies in stable, fully enterally fed preterm infants have shown that episodes of both hypoglycemia and hyperglycemia are not uncommon. For example, MolaSchenzle et al. [16] reported that in very low birth weight infants at approximately 5 weeks of age (N ¼ 51), episodes of low [<45 mg/dl (<2.6 mmol/ l)] and high [>150 mg/dl (>8.3 mmol/l)] interstitial glucose concentrations were detected in 41 and 71% of infants, respectively. By the time of primary hospital discharge, Pertierra-Cortada et al. [17] found that 10% of very preterm infants (N ¼ 60) continued to have episodes of low interstitial glucose [45 mg/dl (2.5 mmol/l)] for more than 30 min, 23% had isolated hyperglycemia [140 mg/dl (7.8 mmol/l)] for more than 30 min and 13% had both. It is not known if this late glucose instability contributes to neurodevelopment impairment, nor if the glucose instability seen in these infants can or should be modified.
IS CONTINUOUS GLUCOSE MONITORING A RELIABLE MEASURE OF NEONATAL GLUCOSE CONCENTRATIONS?
CGM relies on a continuous shifting internal algorithm to convert the sensor current to blood glucose concentration, adjusted by regular calibration against blood glucose measurements [2 & ]. CGM has potential for relatively large errors, and this has three main components: zero-mean error, drift and diffusion time lag. Zero-mean error is the random error of the sensor, which may be considerable due to the sensor technology and its interstitial location. Drift refers to shifts in sensor output between calibration points due to corrosion or biofilm build up on the needle surface, such that different currents are generated by the same blood glucose concentration. The potential for sensor drift is well recognized in adults but has not been assessed in neonates. The diffusion of glucose between the vascular and interstitial compartments also creates a time lag. In lambs, this is approximately 20 min [18] , which is consistent with indirect evidence in neonates [6] . A practical consequence of this time lag is that CGM has increasing positive error when blood glucose concentration is falling and increasing negative error when blood glucose concentration is rising.
CGM point accuracy is usually expressed as mean absolute relative difference (MARD), defined as the mean of the absolute differences between CGM and simultaneous reference values as a percentage of the reference value. Errors of 13% or less are generally considered acceptable. Accuracy of CGM has been assessed in three neonatal studies. Beardsall et al. reported MARD of 9% but Wackernagel et al. found greater errors with MARD of 18%. Tiberi et al. did not report MARD but found that more than a quarter of CGM values were more than 20% from the reference value. Errors may be even larger at extreme glucose concentrations or when glucose concentrations are changing rapidly. Thus, although Bearsdall et al. reported acceptable overall error, the positive predictive value was poor for hypoglycemia (40%) and only modest for hyperglycemia (90%). Importantly, these studies included very few values in the low glucose range, and only glucometers rather than a reliable reference method were used for calibration or evaluation of the device.
CGM trending, that is, the rate and direction of change, may be important clinically but assessment of trend accuracy requires a different approach [7 && ,19] , and this has not been measured in neonates. In addition, little attention has been given to optimization of CGM calibration. Use of an accurate blood glucose measurement, such as by gas or laboratory analyzer, is likely to improve accuracy, as is recalibration during periods of low trending. Tiberi et al. compared thrice and twice daily calibration and found no difference in CGM accuracy. This probably reflects the fact that most CGM devices employ multiple point, weighted calibration, which means that each calibration value influences CGM measurements for up to 24 h, depending on the device algorithm. Point-to-point calibration using accurate glucose concentrations from a blood gas analyzer may be more appropriate for neonatal intensive care, but this option is currently not available in real-time.
SHOULD CONTINUOUS GLUCOSE MONITORING BE USED IN NEONATAL INTENSIVE CARE?
CGM has promise as a tool for reducing the frequency of blood sampling and improving glucose stability by adjusting glucose intake in real-time according to individual metabolic requirements. However, caution is required before this technology is adopted into neonatal practice as there are very few data from randomized trials on the short-term clinical effects of CGM, and no data on longer term outcomes. Without this information, CGM could lead to increased intervention that may be of little benefit or even harmful.
Further research is needed in several areas before CGM can be considered for routine use in neonatal intensive care. First, CGM point accuracy needs to be evaluated against a reliable measure of blood glucose concentration, such as a blood gas analyzer, with sufficient samples in the low glucose range and during fluctuating glucose concentrations. Assessment of trend accuracy is also required. A better understanding of CGM reliability is important as this has implications for whether CGM is used primarily to guide timing of blood glucose measurements or whether CGM data are used directly in clinical decision-making. It is also important for determining the alarm limits that should be used with CGM to indicate need for a clinical response.
Second, further data are needed on the impact of different calibration methods on the accuracy of neonatal CGM. It is currently not known whether all blood glucose measurements should be used in CGM calibration or only certain measurements, for example those within the target blood glucose range or during periods of low trending. Information is also needed on the frequency and extent of sensor drift, and the situations in which it is most likely to occur, as this may help to determine the optimal frequency of calibration.
Third, more information is needed about which CGM parameters are most useful for guiding clinical care. With real-time CGM, alarms can be set at fixed thresholds and for trending (rate of change), and some devices provide prediction alarms based on proprietary algorithms. Graphical display of interstitial glucose concentrations is also provided. The utility of different parameters and alarms will depend somewhat on whether CGM is used for predictive or corrective action, and whether management is aimed at minimizing extreme excursions or maximizing time within a central range. The benefit of CGM may also be influenced by whether it is combined with clinician or computer-guided adjustment of glucose and nutritional intake.
CONCLUSION
The use of subcutaneous CGM sensors in neonates appears to be well tolerated and feasible, even in very preterm infants. CGM has the potential to reduce the frequency of blood sampling and improve detection and prevention of hypoglycemic and hyperglycemic episodes. However, CGM devices have neither been designed nor approved for use in neonates, and there is potential for harm with increased intervention. Before this technology is introduced into routine neonatal care, further information is needed about reliability, calibration and interpretation of CGM. At present, CGM should remain a research tool until clinical benefit is demonstrated in randomized trials that include long-term outcome data.
